Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970003/S248

VNS Therapy System

LivaNova USA, Inc. · Decision date Sep 5, 2025

FDA DECISIONP970003/S248

What did the FDA approve?

FDA records P970003/S248 as a supplement to PMA P970003, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 5, 2025.

FDA approval order statement

Approval for:1. VNS Therapy Epilepsy Physicians Manuals:Update to create a new Management of Depression as a Comorbidity section to inform physicians that depression is a common comorbidity for epilepsy patients and to follow standard medical practice for follow up with these patients and monitoring of their depressive symptoms. Document 26-0011-0100 (Epilepsy Manual; Appendix 1, page 117) New Section added to the Post-Implant Management Chapter: Follow-up Visits: Long-Term Follow Up Section- 7.1.2.2.1 Management of Depression as a Comorbidity:Depression is a common comorbidity in patients with epilepsy. In accordance with standard medical practice, patients with a current or prior diagnosis of depression should be advised to report any new or worsening depressive symptoms, including suicidal ideation.2. VNS Therapy Epilepsy Patient Guide:Update to create a new Patients with Depression section to inform patients that may also have depression to follow up with their doctor if they have new or worsening depressive symptoms. Document 26-0011-1600 (Epilepsy Patient Guide; Appendix 2, page 19). New section added to the Follow Up After Surgery Chapter: After Treatment Begins Section- 6.4.3 Patients with Depression:Some people with epilepsy also have depression. If you have depression now or had it in the past, it is important to monitor your mood and mental health. Contact your doctor if you notice any new or worsening depressive symptoms, including suicidal thoughts.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Neurology
Decision date
Sep 5, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P970003/S248
Regulatory pathway
PMA supplement
Product code
LYJ
Decision code
APPR
Decision date
Sep 5, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.

Product code
LYJ
FDA device class
3

For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P970003 · Original PMA

    VNS THERAPY SYSTEM

  2. P970003/S248 received

    Application receipt date recorded by FDA.

  3. P970003/S248 · FDA decision

    Special (Immediate Track)

  4. P970003/S251 · Related supplement

    VNS Therapy Model 3100 Programmer, VNS Therapy Model 2000 Programming Wand

Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970003

Product / regulatory recordCompanyPathwayDecision dateSource
LivaNova USA, Inc.PMA approvalJul 16, 1997FDA
VNS Therapy SystemP970003/S250
LivaNova USA, Inc.PMA supplementSep 12, 2025FDA
LivaNova USA, Inc.PMA supplementNov 25, 2025FDA
VNS THERAPY SYSTEMP970003/S252
LivaNova USA, Inc.PMA supplementDec 17, 2025FDA
VNS Therapy SystemP970003/S253
LivaNova USA, Inc.PMA supplementMar 4, 2026FDA
VNS Therapy SystemP970003/S249
LivaNova USA, Inc.PMA supplementAug 12, 2026FDA
VNS Therapy SystemP970003/S254
LivaNova USA, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records